Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD.
The speaker discusses efficacy results of clinical trials, specifically focusing on the EASI (eczema area and severity index) 75 endpoint for patients using a tapinarof. In both ADORING 1 and ADORING 2 trials, the speaker notes similar outcomes with approximately 55.8% and 59.1% of patients achieving EASI75, respectively, after 8 weeks of once-daily application. These results are significantly higher than the vehicle-only group, emphasizing the drug's effectiveness. The trials, lasting 8 weeks, stand out in a field where many studies extend to 12 or 16 weeks. The speaker highlights the reproducibility of data between the 2 trials, attributing success to both the vehicle and tapinarof.
The brevity of the trial, combined with a high level of patient adherence, contributes to the positive outcomes, challenging previous assumptions about topical therapies. The speaker expresses excitement about the drug's potential to address moderate to severe atopic dermatitis, comparing its efficacy to systemic therapies. Despite focusing on EASI75, typically not a primary concern for topical treatments, the speaker finds the results encouraging and believes the data signifies a positive shift in the field of dermatological drug development.
Video synopsis is AI-generated and reviewed by Dermatology Times editorial staff.